Hopes for a new medicine to assist people afflicted with ALS were dashed by negative results from a large clinical trial reported Tuesday.

The experimental drug, tirasemtiv, failed to slow the decline in lung function any better than a placebo, said Cytokinetics (CYTK), the drug’s maker. The phase 3 clinical trial enrolled more than 700 people with ALS, the degenerative nerve disorder that robs people of the ability to move or breathe.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It seems that progress on ALS drugs is elusive. Maybe targeting an aspect of the disease process or mechanism is the wrong approach. Maybe we need to go upstream, and target what triggers the disease process or mechanism. This likely varies by the individual. Just as we don’t have one but many breast cancers, we have not one but many combinations of gene variants, cumulative exposures, and epigenetic and phenotypic changes that lead to the devastating disease of ALS.

    There are a small number of physicians treating chronic diseases this way, in which each patient becomes an N of 1, and their particular disease triggers are examined, tested and treated to strengthen their immune and neurological systems, and arrest and partially reverse the disease process.

    At a medical conference in September, I heard a retired construction executive tell the story of his recovery from an 80% diagnosis of ALS. The executive wrote an inspiring short self-published book, An Unexpected Journey: Searching for a cause and finding hope in the battle against ALS. He wants his story to get out, to perhaps help others who otherwise have no hope. You can order it from his blog here: http://www.stlblog.constructforstl.org/blog/2017/6/8/an-unexpected-journey.

    The point of anecdotes and patient stories is not to give false hope, but to raise new angles and avenues for exploration, for research and clinical validation. Perhaps ALS has multiple causes and some are reversible, or perhaps there are conditions that mimic ALS, and some patients can benefit by being screened and treated for those. Perhaps more physicians will go upstream and look for causes. Perhaps more pharma companies will begin to research, test and validate some of these approaches. Will they, if there is not a patent prospect at the end of the rainbow? If not them, who?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy